Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 16/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25423049 | 0.84 | RXFP1 (0.53) | RXFP1SMN1; SMN2P2RX1PTGS1LMNA | |
| SCHEMBL4016155 | 0.82 | RAF1 (0.58) | MAPT | |
| SCHEMBL25421516 | 0.80 | RXFP1 (0.52) | RXFP1SMN1; SMN2P2RX1PTGS1LMNA | |
| SCHEMBL29550365 | 0.79 | RXFP1 (0.57) | RXFP1SMN1; SMN2P2RX1PTGS1 | |
| SCHEMBL22915771 | 0.79 | MEN1 (0.54) | LMNAMAPT | |
| SCHEMBL5488788 | 0.78 | GAA (0.59) | RXFP1P2RX1PTGS1LMNAMAPT | |
| SCHEMBL2887561 | 0.77 | BRAF (0.58) | P2RX1PTGS1LMNAMAPT | |
| SCHEMBL29536884 | 0.77 | BRAF (0.58) | P2RX1PTGS1LMNAMAPT | |
| SCHEMBL59298 | 0.77 | KMT2A (0.54) | SMN1; SMN2LMNAMAPT | |
| SCHEMBL11308212 | 0.77 | PTGS1 (0.78) | RXFP1SMN1; SMN2P2RX1PTGS1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | RXFP1 3174/4885SMN1; SMN2 4067/4885P2RX1 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.